Gyrophoric Acid

Gyrophoric Acid

SCHEMBL3800330

Cc1cc(OC(=O)c2c(C)cc(OC(=O)c3c(C)cc(O)cc3O)cc2O)cc(O)c1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 1.00
HPGD P15428 3/20 1.00
KMT2A Q03164 2/20 1.00
MAPK1 P28482 2/20 1.00
MEN1 O00255 1/20 1.00
ALDH1A1 P00352 1/20 1.00
ALOX15 P16050 1/20 1.00
HSD17B10 Q99714 1/20 1.00
POLB P06746 2/20 0.80
ACHE P22303 2/20 0.71
PTPN1 P18031 4/20 0.64
SMN1; SMN2 Q16637 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
PTPN11 Q06124 2/20 0.56
PTPN2 P17706 1/20 0.56
PTGES O14684 3/20 0.52
TOP2A P11388 1/20 0.52
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lecanoric Acid SCHEMBL29393660 1.00 CYP3A4 (1.00) CYP3A4HPGDKMT2AMAPK1MEN1
Lecanoric Acid SCHEMBL3797774 1.00 CYP3A4 (1.00) CYP3A4HPGDKMT2AMAPK1MEN1
Evernic Acid SCHEMBL2552354 0.89 POLB (1.00) CYP3A4HPGDKMT2AMAPK1MEN1
SCHEMBL30057138 0.89 CYP3A4 (0.79) CYP3A4HPGDKMT2AMAPK1MEN1
Orsellinic Acid SCHEMBL522294 0.84 CYP3A4 (1.00) CYP3A4HPGDKMT2AMAPK1MEN1
SCHEMBL1898807 0.84 CYP3A4 (0.72) CYP3A4HPGDKMT2AMAPK1MEN1
SCHEMBL9741729 0.84 CYP3A4 (0.72) CYP3A4HPGDKMT2AMAPK1MEN1
Lecanorin SCHEMBL22799168 0.84 CYP3A4 (0.72) CYP3A4HPGDKMT2AMAPK1MEN1
SCHEMBL5603959 0.83 CYP3A4 (0.70) CYP3A4HPGDKMT2AMAPK1MEN1
SCHEMBL10607968 0.81 CYP3A4 (0.68) CYP3A4HPGDKMT2AMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230101362-A1 RNA STABILIZATION TEAM MEDICAL LLC 2023-03-30 US claimed
US-20220175713-A1 DEPSIDE TRIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION NESTLE SA (CH) 2022-06-09 US claimed
EP-3946310-A1 DEPSIDE TRIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION Société des Produits Nestlé S.A. (CH) 2022-02-09 EP claimed
CN-113613648-A Depsipeptide compounds for skeletal muscle regulation 雀巢产品有限公司 2021-11-05 CN claimed
WO-2020193493-A1 DEPSIDE TRIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION Société des Produits Nestlé S.A. (CH) 2020-10-01 WO claimed
WO-2008109521-A2 METHOD OF TREATMENT USING ATRANORIN UNIVERSITY OF SOUTH FLORIDA (US) 2008-09-12 WO claimed
US-20250368695-A1 Atranorin biosynthesis gene derived from lichens and uses thereof INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) 2025-12-04 US disclosed
US-20240058246-A1 LIPO-AMINO ACID ALKYL ESTERS AS SPF BOOSTERS PRODOTTI GIANNI S.R.L. (IT) 2024-02-22 US disclosed
US-11793738-B2 Lipo-amino acid alkyl esters as SPF boosters PRODOTTI GIANNI S.R.L. (IT) 2023-10-24 US disclosed
US-20230101362-A1 RNA STABILIZATION TEAM MEDICAL LLC 2023-03-30 US disclosed
WO-2023044455-A2 RNA STABILIZATION TEAM MEDICAL LLC (US) 2023-03-23 WO disclosed
WO-2022260402-A1 ATRANORIN BIOSYNTHESIS GENE DERIVED FROM LICHEN AND USE THEREOF 순천대학교 산학협력단 2022-12-15 WO disclosed
EP-4011357-A1 LIPO-AMINO ACID ALKYL ESTERS AS SPF BOOSTERS Prodotti Gianni S.r.l. (IT) 2022-06-15 EP disclosed
CN-101433339-A Special sausage with delicious flavour for strongly tonifying kidney and replenishing vital essence MAOSHUN WU (CN) 2009-05-20 CN disclosed
WO-2008109521-A3 METHOD OF TREATMENT USING ATRANORIN UNIV SOUTH FLORIDA (US) 2008-12-24 WO disclosed
WO-2008109521-A2 METHOD OF TREATMENT USING ATRANORIN UNIVERSITY OF SOUTH FLORIDA (US) 2008-09-12 WO disclosed
WO-2008109521-A2 METHOD OF TREATMENT USING ATRANORIN UNIVERSITY OF SOUTH FLORIDA (US) 2008-09-12 WO disclosed
US-20070099993-A1 Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum) COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2007-05-03 US disclosed
EP-1675020-A2 Parser Xerox Corporation (US) 2006-06-28 EP disclosed
US-20060136196-A1 Bi-dimensional rewriting rules for natural language processing XEROX CORPORATION 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11793738-B2 Lipo-amino acid alkyl esters as SPF boosters SLC43A1, CUTA, AADAT CYP3A4 2017/4885HPGD 2828/4885KMT2A 1621/4885
US-20220175713-A1 DEPSIDE TRIMERIC COMPOUNDS FOR SKELETAL MUSCLE MODULATION MYLK2, CPT1B, MSTN CYP3A4 4819/4885HPGD 1474/4885KMT2A 3189/4885
US-20240058246-A1 LIPO-AMINO ACID ALKYL ESTERS AS SPF BOOSTERS SLC43A1, CUTA, AADAT CYP3A4 2017/4885HPGD 2828/4885KMT2A 1621/4885
US-20070099993-A1 Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum) MRM1, CYP51A1, ORMDL3 CYP3A4 3822/4885HPGD 2915/4885KMT2A 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.